Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, ...